Phase I study of CART-ddBCMA in R/R multiple myeloma Matthew J. Frigault, MD, Harvard Medical School, Boston, MA, discusses the safety and efficacy results of a Phase I study of CART-ddBCMA, an autologous anti-BCMA CAR-T cell therapy that utilizes a novel, synthetic binding domain, called a D-Domain, instead of a typical scFv binder, in patients […]

Read More